Cdtx stock rating
Cidara Therapeutics (CDTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. CDTX | Stock Snapshot - Fidelity Apr 03, 2020 · Stock quote and company snapshot for CIDARA THERAPEUTICS INC (CDTX), including profile, stock chart, recent news and events, analyst opinions, and research reports. CDTX Price Target | Cidara Therapeutics Stock Forecast ...
CDTX Stock Price & Charts | Cidara Therapeutics
In depth view into CDTX (Cidara Therapeutics) stock including the latest price, Target on Cidara Therapeutics to $4 From $5, Maintains Outperform Rating. 6 days ago Analyst Kevin DeGeeter maintained a Buy rating on Cidara Therapeutics today and set a price target of $6.00. The company's shares closed last 6 Mar 2020 Cidara Therapeutics (CDTX) Technical Analysis. When it comes to the technical analysis of CDTX stock, there are more than several important Quant Ratings · Retirement Daily · Stocks Under $10 · Trifecta Stocks · Top Stocks · Real Money Pro Portfolio · Chairman's Club · Compare All · JIM CRAMER. 15 Jan 2020 See the CDTX stock analysis. TipRanks offers investors the latest insight into eight different sectors by tracking the activity of over 5,000 Wall 5 Mar 2020 1 of the 17 analysts rate the stock as a “Sell”, while 0 has rated it as Cidara Therapeutics Inc. (NASDAQ:CDTX), on the other hand, is trading
Cidara Therapeutics Inc (CDTX) Quote | Morningstar
CDTX | Stock Snapshot - Fidelity Apr 03, 2020 · Stock quote and company snapshot for CIDARA THERAPEUTICS INC (CDTX), including profile, stock chart, recent news and events, analyst opinions, and research reports. CDTX Price Target | Cidara Therapeutics Stock Forecast ... See Cidara Therapeutics price target based on 4 analysts offering 12 month price targets for Cidara Therapeutics in the last 3 months. The average price target is $5.33 with a high forecast of $6.00 and a low forecast of $4.00. The average price target represents a 123.01% increase from the last price of … Cidara Therapeutics (NASDAQ:CDTX) Stock Rating Lowered by ... ValuEngine cut shares of Cidara Therapeutics (NASDAQ:CDTX) from a hold rating to a sell rating in a report published on Friday morning, ValuEngine reports. Other research analysts also recently issued reports about the stock. Zacks Investment Research downgraded shares of Cidara Therapeutics from a buy rating to a hold rating in a report on Monday, […] Cidara Therapeutics Inc (CDTX) Operating Performance ...
Mar 23, 2020 · Review CDTX return on assets, equity, and invested capital, margins, and turnover. CDTX Morningstar Rating Rating as of Mar 23, 2020. Quote Stock Style Large-Cap Value ;
CDTX Price Target and Analyst Ratings (Cidara Therapeutics)
CDTX Stock Rating and Data | Cidara Therapeutics ...
Mar 05, 2020 · In a report released today, Alan Carr from Needham maintained a Buy rating on Cidara Therapeutics (CDTX – Research Report), with a price target of $6.00.The company’s shares closed last Monday at $3.15. According to TipRanks.com, Carr is a 1-star analyst with an average return of -1.3% and a 40.7% success rate. Carr covers the Healthcare sector, focusing on stocks such as ACADIA Cidara Therapeutics - CDTX - Stock Price & News | The ... Real time Cidara Therapeutics (CDTX) stock price quote, stock graph, news & analysis. Real time Cidara Therapeutics (CDTX) stock price quote, stock graph, news & analysis. Company Rating. What CDTX - Cidara Thera Stock Analyst Ratings - Barchart.com Unlike Barchart Opinions (which calculate the Buy/Sell rating using a variety of short-medium and long-term technical indicators), the Analyst Ratings are more of a short-term indicator that gives you a feel for how outside industry experts are weighing in on a stock.
CDTX News: Earnings, Analyst Moves, and More Filter CDTX News Items All News Types Featured Stories Corp. News Earnings Hedge Fund Insider Buying Mgmt Change New Coverage (Bullish) Product News PT Lowered PT Raised PT Set (Bullish) Rating Reiterated (Bullish) Stock Offering Upgrade